Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Study of ALXN2050 MR Formulations vs IR Reference in Healthy Adults
NCT05780645Phase 1Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Mar 2023
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vemircopan in paroxysmal nocturnal hemoglobinuria (PNH) and myasthenia gravis (MG) (2 cohorts), sponsored by Alexion Pharmaceuticals. Primary endpoints: Maximum Observed Plasma Concentration, Time to Reach Cmax and 1 more. Started Mar 2023; status: completed.
02
Drugs
vemircopan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT05780645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05780645.